# Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects

> **NCT05833906** · PHASE1 · COMPLETED · sponsor: **CK Regeon Inc.** · enrollment: 52 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CKR-051 Dose 1
- **DRUG:** CKR-051 Dose 2
- **DRUG:** CKR-051 Dose 3
- **DRUG:** CKR-051 Dose 4
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05833906
- **Lead sponsor:** CK Regeon Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-25
- **Primary completion:** 2024-01-08
- **Final completion:** 2024-01-08
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05833906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05833906, "Safety, Tolerability, and Pharmacokinetic Evaluations of CKR-051 After Transdermal Administration in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05833906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*